How GLP-1s Are Shifting Pharma Commercialization Trends

The GLP-1 market's evolution from a niche injectable class to a high-volume category is shifting trends in pharmaceutical commercialization. In the first part of his interview series with Pharmaceutical Commerce, Roel van den Akker, Deals partner at PwC, discusses the influence of blockbuster GLP-1s on the broader pharmaceutical landscape.

Providing insight from his experience in M&A, Van den Akker notes over the last decade, pharma has focused on ultra-rare diseases and niche indications that commanded high prices. While this is still a focus, the GLP-1 journey signals a shift to large Total Addressable Markets (TAMs) with more moderated, average pricing. As the market grows from just injectables to oral formulations and competition increases, the focus is shifting toward large patient populations. This transition is prompting a rethinking of the traditional "niche" blueprint, positioning high-volume uptake and improved health economic outcomes as the primary drivers for the next generation of sector champions.

In this interview, van den Akker breaks down how the GLP-1 journey is pushing pharma to rethink commercialization and market access from the ground up. He examines what payer negotiations could look like in a more competitive, price-compressed environment, how distribution infrastructure must adapt to serve massive patient populations, and why the blueprint being written today by GLP-1 market leaders could define future market trends.